par Van Cutsem, Eric;Tejpar, Sabine;Vanbeckevoort, Dirk;Peeters, Marc;Humblet, Yves;Gelderblom, Hans;Vermorken, Jan B;Viret, Frederic;Glimelius, Bengt;Gallerani, Elisa;Hendlisz, Alain 
;Cats, Annemieke;Moehler, Markus;Sagaert, Xavier;Vlassak, Soetkin;Schlichting, P.;Ciardiello, Fortunato
Référence Journal of clinical oncology, 30, 23, page (2861-2868)
Publication Publié, 2012-08
;Cats, Annemieke;Moehler, Markus;Sagaert, Xavier;Vlassak, Soetkin;Schlichting, P.;Ciardiello, FortunatoRéférence Journal of clinical oncology, 30, 23, page (2861-2868)
Publication Publié, 2012-08
Article révisé par les pairs
| Résumé : | Skin toxicity in patients receiving cetuximab has been associated positively with clinical outcome in several tumor types. This study investigated the effect of cetuximab dose escalation in patients with irinotecan-refractory metastatic colorectal cancer who had developed no or mild skin reactions after 21 days of treatment at the standard dose. This article reports clinical and pharmacokinetic (PK) data. |
